Evotec AG plans to acquire Cyprotex PLC, a preclinical CRO specializing in ADME-Tox and DMPK, for £55.4 million in cash. The proposed acquisition has been unanimously recommended by the board of Cyprotex and is expected to close by the end of the year.   Cyprotex specializes in early drug screening to support regulatory requirements and reduce the reliance on animal testing for the Pharmaceutical, Chemical, Agrochemical and Cosmetics markets. Cyprotex, headquartered in the UK, has 136 employee...